Background: In 2017, a European Food Safety Authority (EFSA) opinion on the use of glutamate and its salts as food additives led to an Acceptable Daily Intake (ADI) of 30 mg/kg body weight/day. Then, in 2021, an EFSA statement presented a proposal for harmonizing the establishment of Health-Based Guidance Values for nutrients that are also regulated substances (including food additives). The present review argues that the 2017 glutamate ADI is unsuitable because safety of glutamate should firstly consider its status as a nutrient and not only as an additive.
Summary: Glutamate is a non-essential amino acid playing a key role in nitrogen homeostasis. The dietary exposure to glutamate in adults is extensive, due to its ubiquitous presence in foods, under three forms: bound to proteins, naturally free and free form added as an additive. Glutamate naturally included in proteins is the major source of dietary glutamate. Thus, since it plays a role in nitrogen homeostasis, it is a nutrient before being an additive. Its pharmacokinetics are largely impacted by concomitant food intake, but the extent to which plasma glutamate concentration must rise to have deleterious effects is never encountered in humans consuming glutamate in their daily diets. This is due to the fact that glutamate is highly metabolized in the splanchnic area.
Key Message: Glutamate should be considered as a safe nutrient before being considered as an additive by risk assessor.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227671 | PMC |
http://dx.doi.org/10.1159/000522482 | DOI Listing |
BMJ Open
January 2025
Institute of Diabetes Research, Helmholtz Munich German Research Center for Environmental Health, Munich, Germany
Introduction: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the disease and a significant reduction in clinical symptoms. The European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception (EDENT1FI) represents a pioneering effort to advance early detection of type 1 diabetes through public health screening.
View Article and Find Full Text PDFBMC Plant Biol
January 2025
Hebei Agricultural University, Baoding, China.
Background: Nitrogen (N) deposition has become a major driving factor affecting the balance of terrestrial ecosystems, changing the soil environment, element balance and species coexistence relationships, driving changes in biodiversity and ecosystem structure and function. Human-induced nitrogen input leads to a high NH/ NO ratio in soil. However, relatively few studies have investigated the effects of different nitrogen sources on forest plant-microbial symbionts.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Anesthesiology & Perioperative Medicine, University of Rochester, Rochester, New York, United States of America.
Neurodegenerative diseases are often characterized by mitochondrial dysfunction. In Alzheimer's disease, abnormal tau phosphorylation disrupts mitophagy, a quality control process through which damaged organelles are selectively removed from the mitochondrial network. The precise mechanism through which this occurs remains unclear.
View Article and Find Full Text PDFCell Rep
January 2025
State Key Laboratory of Efficient Utilization of Arid and Semi-arid Arable Land in Northern China, Key Laboratory of Microbial Resources Collection and Preservation, Ministry of Agriculture and Rural Affairs, Institute of Agricultural Resources and Regional Planning, Chinese Academy of Agricultural Sciences, Beijing 100081, China. Electronic address:
Pseudomonas syringae deploys a type III secretion system (T3SS) to deliver effector proteins to facilitate infection of plant cells; however, little is known about the direct interactions between T3SS components and plants. Here, we show that the specialized lytic transglycosylase (SLT) domain of P. syringae pv.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!